Tying price to value — from drugs to hip surgery — still elusive

first_img What’s included? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Health Log In | Learn More Tying price to value — from drugs to hip surgery — still elusive What is it? BOSTON — As the cost of health care rises, academic and industry leaders batted around ideas to make medicine more affordable by having people pay for the benefit they accrue rather than the specific services they receive.Called “value-based care,” the concept is complicated and amorphous — but it touches all areas of health care, from hospital procedures to medical research to pharmaceutical pricing. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Ike Swetlitz May 2, 2017 Reprints Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Alden Pellett/AP GET STARTED Tags drug pricingpharmaceuticalsSTAT+last_img

Leave a Comment

Your email address will not be published. Required fields are marked *